AbbVie stock heads into JPM Healthcare week as $30B deal talk creeps back

New York, January 11, 2026, 11:10 EST — Market closed

AbbVie shares fell 1.8% to close Friday at $220.08.
Talk of deals is heating up as the J.P. Morgan Healthcare Conference approaches.
Key dates ahead: conference appearance on Jan. 14, ex-dividend on Jan. 16, and earnings report due Feb. 4.

AbbVie Inc. (ABBV.N) closed Friday down 1.8% at $220.08. As U.S. markets remain closed over the weekend, chatter about a potential deal lingers heading into Monday.

The J.P. Morgan Healthcare Conference week draws attention now, serving as a hotspot for new guidance, pipeline updates, and those crucial side-room talks that often spark M&A activity. For major drugmakers, it’s also the moment investors demand a clear answer: should they buy growth or build it themselves?

Deal advisers told Reuters they expect a surge in large healthcare M&A deals in 2026 as companies grapple with patent expiries and a potentially softer antitrust environment. “That has made people dust off the playbook on the art of the possible,” said JPMorgan banker Jeremy Meilman. Reuters also reported healthcare M&A volume jumped 56% in 2025. Against this backdrop, rumors of AbbVie and Merck eyeing Revolution Medicines briefly pushed the biotech’s value up 34% to around $20 billion, despite AbbVie denying any talks and key trial results still months away. (Reuters)

AbbVie slipped Friday while the S&P 500 climbed 0.65%. ABBV clearly reacted to company-specific news, not the rally elsewhere. (MarketWatch)

AbbVie plans to address investors on Wednesday, Jan. 14, with management taking part in a fireside chat at 10:15 a.m. Central time. The session will be webcast live on AbbVie’s investor website. (AbbVie News Center)

Income-focused investors should mark their calendars: ABBV carries a $1.73 quarterly dividend with an ex-dividend date on Jan. 16 — the cutoff day for snagging the next payout. These dates can move the needle, especially in a week where headlines often steer the action more than fundamentals. (Yahoo Finance)

AbbVie’s CEO Robert Michael tied the increased dividend to strong business performance, announcing the company is “once again raising our quarterly cash dividend.” The new payout, set for Feb. 17 to shareholders of record on Jan. 16, boosts the quarterly rate from $1.64 to $1.73. (PR Newswire)

Big takeovers seldom go off without a hitch. Premiums often balloon quickly, and buyers may find themselves paying for “strategic” value rather than earnings. Meanwhile, regulators have numerous tools to drag out the process.

AbbVie will release its full-year and fourth-quarter 2025 results on Feb. 4, before the market opens, with a webcast scheduled for 8 a.m. Central time, the company announced. All eyes will be on the 2026 outlook and whether any deal rumors are gaining traction.

Khadija Saeed Latest posts

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

View all

Phibro Animal Health priced below intrinsic value, DCF shows gap
January 11, 2026, 3:57 PM EST. Phibro Animal Health's stock closed at $39.44 as investors weigh a multi-year rally and a defensives-heavy sector backdrop. Over the last week it rose 5.7%, fell 1.8% last month, with a 5.7% gain year-to-date and a 1-year gain near 99.9%, plus a 3-year gain around 190.7% and a 5-year gain of about 110.2%. On Simply Wall St's valuation, PAHC scores 2/6 and is labeled undervalued on two checks. A Discounted Cash Flow (DCF) model estimates an intrinsic value near $97.41 per share, implying a roughly discount of 59.5% to the current price. The analysis uses a 2-stage Free Cash Flow to Equity approach; latest twelve months' FCF ≈ $26.9 million, projected to $205.1 million in 2035. The stock trades at a P/E of 23.6x, above the Pharmaceuticals industry average of about 19.6x.